LTBP2, respectively, are listed in the Human Gene Mutation database. In patients with PCG, early diagnosis is important for effective treatment of the disease with surgical interventions (e.g., trabeculotomy, trabeculectomy, goniotomy, or deep sclerectomy), use of drainage implants, or correcting refractive errors and amblyopia. Therefore, identifying individuals at risk for inheriting pathogenic variant(s) as soon as possible after birth has considerable ramifications for diagnosis, management, and treatment of PCG and to prevent unnecessary health care costs [5] .
To investigate the etiology of the disease at the molecular level and to improve genetic diagnosis, we ascertained a large cohort of consanguineous Pakistani families segregating PCG. We performed candidate genes screening with Sanger sequencing and whole exome sequence (WES) analysis to identify the underlying genetic cause of PCG in the cohort. In this study, we report identification of five known and three novel variants of CYP1B1 segregating in 14 families with PCG. We did not find a pathogenic allele in CYP1B1 and LTBP2 in 22 of the 36 families (61%), which suggests genetic heterogeneity of PCG in the Pakistani population.
METHODS

Subjects and clinical evaluation:
The present study was approved by IRB committees of the participating institutions in the United States and Pakistan. All methods used in the study followed the precepts of Declaration of Helsinki and were in compliance of the ARVO statement on human subjects. Informed written consent was obtained from all individuals before inclusion in the study. A total of 423 individuals including 227 males (of which 79 had glaucoma) and 196 females (71 affected) with the ages ranging from 1 year old to 65 years old were recruited from Sindh and Punjab Provinces of Pakistan. Detailed interviews were conducted with family members to gather information on pedigree structure, comorbidities, onset of disease, and initial symptoms. The clinical diagnosis was based on presenting symptoms, physical and ophthalmic examinations, fundoscopy, or slit-lamp microscopy. The DNA was extracted from whole blood by using the inorganic method as described previously Grimberg et al 1989 [9] .
Known genes screening and exome sequencing: Before exome sequencing, we performed Sanger sequencing on one affected individual from 24 of the 36 families with glaucoma for known PCG genes, CYP1B1 and LTBP2. Primers for Sanger sequencing were designed using Primer3. PCR amplification was performed as follows: 95 °C: 2 min (1X), 95 °C: 30 sec; annealing temperature: 30 sec; 72 °C: 1 min (35X), 72 °C: 7 min (1X), 25 °C: 5 min (1X) by using EconoTaq Plus 2X Master mix. and DNA sequencing were performed as described previously [10] . WES was performed on the remaining 12 families and on the families negative for pathogenic variants in CYP1B1 and LTBP2. For WES, genomic libraries were recovered for exome enrichment using the Agilent SureSelect Human Expanded All Exon V5 (62 Mb) kit (Agilent corporation, Santa Clara, CA).. Libraries were sequenced on an Illumina HiSeq2500 (Agilent corporation) with average 100X coverage. Data analysis used the Broad Institute's Genome Analysis Toolkit [11] . Reads were aligned with the Illumina Chastity Filter with the Burrows-Wheeler Aligner [12] . Variant sites were called using the GATK UnifiedGenotyper module. Single nucleotide variant calls were filtered using the variant quality score recalibration method [11] . Filtration of candidate variants was performed as described previously [13] . Sanger sequencing was used to confirm the segregation of the variants identified in the families.
In silico analysis:
The following online pathogenicity prediction programs were used to evaluate the pathogenicity of missense variants: Polymorphism Phenotyping v2 (PolyPhen-2), Sorting Tolerant From Intolerant (SIFT), Mutation Taster, Mutation Assessor, and fathmm. Moreover, ClustalW alignment was used to assess the conservation of the affected amino acid residues.
RESULTS
Clinical findings:
In this study, we enrolled 36 families segregating with primary congenital glaucoma from the Punjab and Sindh provinces of Pakistan (Figure 1 ). The neonatal clinical records of the affected individuals were not available at the time of enrollment. According to the family history, all the affected individuals were reported to have vision problems shortly after birth or in early childhood. The most common features consistent with PCG included high intraocular pressure, reduced visual acuity, increased corneal diameter, and corneal haze ( Figure 1 , Table 1 ). However, high inter-and intrafamilial variability was observed in the severity of PCG in these families (Table 1) . For instance, one affected individual of family PKED05 had no apparent visual impairment or corneal haze, but ophthalmic evaluation revealed high intraocular pressure, while the other affected individuals of the same family had classical symptoms of PCG. Furthermore, a few affected individuals of the families with PCG had low vision and corneal haze only in one eye (Table 1) . However, a few of the participating affected individuals had microphthalmia, and were completely blind at the time of enrollment.
Genetic spectrum: We used candidate genes (CYP1B1 and LTBP2) screening and WES to identify the underlying genetic causes of PCG in the families. We identified eight variants of CYP1B1 cosegregating with PCG in 14 of the 36 families ( Figure 1 , Table 2 ). All of these 14 consanguineous families segregated PCG associated with CYP1B1 variants in a homozygous fashion. Five of these variants have been previously reported to cause PCG in humans, but we also identified three novel variants in CYP1B1 (Table 2) . Almost 75% (six of eight) of the identified variants are present only once in the cohort ( Table 2 ). However, a single variant p.(Arg390His) was found in six of the 14 families with CYP1B1-associated PCG (Table  2) . Surprisingly, we did not find a disease-associated variant of LTBP2 in the cohort, which suggests genetic heterogeneity of PCG in Pakistani families.
Causal variants:
Of the causative variants identified in this study, two were novel missense variants [p.(Leu181Gln and p.(Gln479Arg)] of CYP1B1, cosegregating with PCG in families PKED01 and PKED05, respectively ( Figure  1 ). These missense variants were not found in the Genome Aggregation (gnomAD), Human Gene Mutation (HGMD), and ClinVar databases, and were predicted to be deleterious by various in silico prediction algorithms (Table 2) . Both missense variants affected amino-acid residues that are highly conserved among the CYP1B1 orthologs ( Figure 2 ). We also used the HOPE [14] and Phyre2 [15] 3D modeling prediction programs to further assess the effects of these two missense variants on the secondary structure of the encoded protein. The p.Leu181 and p.Gln479 residues are located in the cytochrome p450 domain. Leucine at position 181 is part of an α-helix and is predicted to be buried in the protein core. Substitution of p.Leu181 with glutamine, which is smaller and less hydrophobic than leucine, does not prefer an α-helix as a secondary structure and leads to the loss of hydrophobic interactions in the protein core. Similarly, the substituting glutamine with arginine at position 479 is predicted to affect the protein stability by introducing protein-folding problems due to its positive charge, which, in turn, could affect the ligand contacts made by one of the neighboring residues.
In two families with PCG (LUPCG01 and GCUF14), we found a novel single nucleotide deletion (c.1325delC), which is predicted to cause premature truncation [p.(Pro442Glufs*15); Table 2 ) of the encoded protein. This variant has low frequency in gnomAD (4.061 × 10 −6 ), but is not registered in HGMD or ClinVar. In two other families (GCFGL02 and GCUF19), we identified two known frameshift variants [c.868dupC, p.(Arg290Profs*37); c.1209InsTCATGCCACC, p.(Thr404Serfs*30)], respectively. Both insertion variants are also predicted to result in premature stop codons and early truncation of CYP1B1.
In this study, the most commonly observed variant was c.1169G>A [p.(Arg390His)], which was found cosegregating with PCG in six families ( Table 2 ). The c.1169G>A variant has relatively low frequency in the gnomAD database (1.017 × 10 −4 ), which includes data of 123,136 exome and 15,496 whole-genome sequences. Therefore, we performed a haplotype analysis using eight closely linked single nucleotide polymorphisms (SNPs) in CYP1B1 to identify potential founder effects for this recurrent variant. Selection of these eight SNPs for haplotype analysis was based on the observance of high heterozygosity (>0.3) in 50 control samples randomly collected from the Pakistani population. The results were consistent with a common ancestor for the c.1169G>A recurrent allele in the Pakistani families in this study (data not shown). ] is predicted to disrupt this hydrogen bond, and interrupt the signal transduction between the two domains of CYP1B1, cause an empty space in the core of the protein, and distort the correct protein folding. The p.Pro437 residue is located on the protein's surface. Prolines are known to be rigid and therefore, induce a special backbone conformation. Replacing a proline with leucine might disturb this special conformation and distort the interactions with other molecules. Finally, the substituting glutamine with arginine at position 479 is predicted to affect the protein stability by introducing protein-folding problems due to its positive charge, which, in turn, could affect the ligand contacts made by one of the neighboring residues.
The arginine at position 390 is highly conserved across CYP1B1 orthologs (Figure 2A) , and is predicted to be protein damaging by several in silico bioinformatics tools ( Table 2) . The 3D protein modeling revealed that the p.Arg390 forms a hydrogen bond and a salt bridge with glutamic acid at position 387, asparagine at position 428, and proline at position 437 ( Figure 2B ). Substitution with a smaller residue histidine [p.(Arg390His)] is predicted to disrupt this hydrogen bond, and interrupt the signal transduction between the two domains of CYP1B1, and thus, is predicted to be pathogenic. In another family with PCG (GCUF22), arginine at position 390 is substituted with cysteine [p.(Arg390Cys); Table  2 ], which is also predicted to result in the loss of charge required to keep ionic interactions to make a salt bridge. The p.(Arg390Cys) substitution is also predicted to cause an empty space in the core of the protein and loss of hydrogen bonds and distort the correct protein folding.
Finally, through WES we identified a known missense variant [c.1310C>T, p.(Pro437Leu)] of the CYP1B1 gene in family LUPCG10 (Table 2 ). The proline residue at position 437 is located on the protein's surface. As proline is rigid, p.Pro437 is predicted to induce a special protein backbone conformation at this position. The p.(Pro437Leu) substitution might disturb this special conformation and distort the interactions with other molecules.
DISCUSSION
PCG is one of the most common genetic diseases worldwide. Pathogenic variants in CYP1B1 represent a broad spectrum for PCG at the global level. CYP1B1 is a constituent of cytochrome p450 family genes that are known to be involved in the detoxification of exogenous and endogenous molecules. CYP1B1 also plays a role in developmental processes of eye with an influence on metabolism. In ocular development, retinoic acid and estradiols are the two specific substrates for CYP1B1 [16] . CYP1B1 is known to regulate oxidative homeostasis, and ultrastructural and functional performance of trabecular meshwork tissue in the eye [17] .
This study described the identification of eight allelic variants of CYP1B1 in 14 families with PCG ascertained from different regions of Pakistan. All of these variants were either substitution of the highly conserved residues or predicted to cause early truncation of the encoded protein with determined functional significance, and thus, considered to be disease causing. All of the identified variants segregated with the phenotype with an autosomal recessive pattern of inheritance. Seven of these variants were found only in one to two families, except the p.(Arg390His) allele, which was recurrently found in six families and likely originated from a single ancestral modification incidence. We also identified two novel homozygous missense variants [p.(Leu181Glu and p.(Gln479Arg)] in PKED01 and PKED05, respectively. Each variant results in a disturbed protein local secondary structure.
Ophthalmic evaluation of the affected individuals harboring homozygous variants in CYP1B1 revealed interand intrafamilial variability in the severity of PCG in these families. Variability in the disease manifestation and incomplete penetrance of CYP1B1 alleles have been previously found in consanguineous populations in Saudi Arabia and Pakistan [18, 19] . It is possible that environmental or other epigenetic factors may be the cause of this incomplete penetrance. However, a possible dominant modifier locus has also been proposed [18] , although no modifier gene has been reported yet. Genetically mapping a modifier variant of CYP1B1 in humans is challenging because of the usual limitations in the number of family subjects with incomplete penetrance [18, 19] . Currently, we also cannot rule out the possibility of multiple modifier factors, including genetic and environmental, leading to incomplete penetrance. Modifiers that suppress a mutant phenotype of a Mendelian disorder provide insight into the mechanisms by which organisms can buffer biologic processes to accommodate the adverse effects of genetic mutations [20] [21] [22] [23] [24] . Thus, identification of the modifier of CYP1B1 may point toward possible therapies for individuals with PCG.
Considering the reported frequency of LTBP2 alleles in patients with PCG negative for variants in CYP1B1 [7, 25] , it is surprising that we did not find a pathogenic variant in the coding exons or in the splice junctions of LTBP2 in the PCG cohort. There are several possible reasons for our failure to detect variants of LTBP2 and CYP1B1 in the remaining 22 families with PCG. For instance, disease-causing variants may alter the sequence of cis-acting regulatory or splicing elements of LTBP2 or CYP1B1 that are necessary for their expression in ocular tissue. Presently, we do not know the location of the regulatory elements of CYP1B1 and LTBP2. Moreover, these results further support the genetic heterogeneity of PCG in the Pakistani population. Currently, we are investigating the exome data of the remaining 22 families with PCG for pathogenic variants at loci (GLC3B; OMIM 600975 and GLC3C; OMIM 613085) that were previously linked with PCG [26, 27] , as well as in genes that were not previously associated with glaucoma.
In summary, we identified three novel and five known variants of CYP1B1 that are associated with PCG in 14 Pakistani families. The data suggest that the variants in CYP1B1 might be responsible for extensive PCG cases in a highly consanguineous population. Detailed functional evaluation of pathogenic variants in CYP1B1 will add to better awareness of the PCG disease mechanism. This study extends the knowledge spectrum of PCG at the molecular level and could lead to the improvement of clinically relevant genetic diagnostic protocols.
